Detection of disease-associated α-synuclein in the cerebrospinal fluid: a feasibility study.
Detection of disease-associated α-synuclein in the cerebrospinal fluid: a feasibility study.
复制标题
DOI:
10.5414/np300796
复制
发表时间:
2014-09
影响因子:
1.1
通讯作者:
Kovacs GG
中科院分区:
文献类型:
--
作者:
Unterberger U;Lachmann I;Voigtländer T;Pirker W;Berghoff AS;Flach K;Wagner U;Geneste A;Perret-Liaudet A;Kovacs GG
With the aim to evaluate the significance and reliability of detecting disease-specific α-synuclein in the cerebrospinal fluid (CSF) we developed an ELISA and bead-assay. We used a commercial antibody (5G4) that does not bind to the physiological monomeric form of α-synuclein, but is highly specific for the disease-associated forms, including high molecular weight fraction of β-sheet rich oligomers. We applied both tests in CSF from a series of neuropathologically confirmed α-synucleinopathy cases, including Parkinson’s disease dementia (PDD) and dementia with Lewy bodies (DLB) (n = 7), as well as Alzheimer’s disease (n = 6), and control patients without neurodegenerative pathologies (n = 9). Disease-specific α-synuclein was detectable in the CSF in a subset of patients with α-synuclein pathology in the brain. When combined with the analysis of total α-synuclein, the bead-assay for disease-specific α-synuclein was highly specific for PDD/DLB. Detection of disease-associated α-synuclein combined with the total levels of α-synuclein is a promising tool for the in-vivo diagnosis of α-synucleinopathies, including PDD and LBD.
登录
查看更多内容
影响因子:
5.3
作者:
Mollenhauer, Brit;Cullen, Valerie;Schlossmacher, Michael G.
通讯作者:
Schlossmacher, Michael G.
影响因子:
12.7
作者:
Kovacs, Gabor G.;Wagner, Uta;Lachmann, Ingolf
通讯作者:
Lachmann, Ingolf
影响因子:
9.9
作者:
Tokuda, T.;Qureshi, M. M.;El-Agnaf, O. M. A.
通讯作者:
El-Agnaf, O. M. A.
影响因子:
8.6
作者:
Parnetti, Lucilla;Chiasserini, Davide;El-Agnaf, Omar
通讯作者:
El-Agnaf, Omar
DOI:
10.1016/j.bbrc.2006.08.024
发表时间:
2006-10-13
影响因子:
3.1
作者:
Tokuda, Takahiko;Salem, Sultan A.;El-Agnaf, Omar M. A.
通讯作者:
El-Agnaf, Omar M. A.